Skip to main content
. Author manuscript; available in PMC: 2016 Nov 15.
Published in final edited form as: Biol Psychiatry. 2015 Feb 7;78(10):693–701. doi: 10.1016/j.biopsych.2015.01.015

Figure 4. Pharmacological inhibition of 5LO modulates tau phosphorylation in the brains of tau transgenic mice.

Figure 4

(A) Representative Western blot analyses for insoluble total tau fraction (HT7) in brain cortex homogenates from htau and htau-zileuton mice. (B) Densitometric analyses of the immunoreactivities to the antibodies shown in panel A (*p<.01; **p<.001; ***p<.0001) (n=6 per group). (C) Representative images of immunohistochemical staining of the brain hippocampal region for MC1 antibody. (D) Representative Western blot analyses for cyclin-dependent kinase (cdk)5, p35, p25, glycogen synthase kinase (GSK3α, GSK3α, p-GSK3α, p-GSK3β), stress activated protein kinase/jun amino terminal kinase (SAPK/JNK1, SAPK/JNK2, p-SAPK/JNK1, p-SAPK/JNK2) and phosphotase protein-2 (PP2)A protein levels in brain cortex homogenates from htau and htau-zileuton mice. (E) Densitometric analyses of the immunoreactivities to the antibodies from the previous panel (*p<.01;**p<.001) (n=6 per group). (F) Cdk5 kinase activity in lysates from brain cortex homogenates for htau and htau-zileuton mice (***p < .001). Values represent mean ± sem (n=10 per group).